Opinion|Videos|June 27, 2024
Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Advertisement
Episodes in this series
- What are the current guideline-recommended systematic treatments for HR-positive/HER2-negative (HR+/HER2-) breast cancer?
- What are some of the differences between the CDK 4/6 inhibitors used in the management of HR+/HER2-? What factors drive treatment decision-making between available options?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
New Bill Would Cap Traditional Medicare Out-of-Pocket Costs at $5000
3
Topical Delgocitinib Improves Chronic Hand Eczema Outcomes Across All Trial Timepoints
4
COA Offers Playbook to Help Community Oncology Practices Navigate AI Partnerships
5